Neurocrine Biosciences Email Format

Biotechnology Research
1,001-2,500 employees
San Diego, CA, USA

Neurocrine Biosciences is a biopharmaceutical company that discovers and develops treatments for neurological, psychiatric, endocrine, and immunological disorders across the United States.

Find contacts at Neurocrine Biosciences

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

firstinitiallast@neurocrine.com

Company Overview

Industry
Biotechnology Research
Founded
1992
Headquarters
San Diego, CA, USA
Revenue
$1B-$2.5B
FUNDING Stage
Public
Key Executives
Kyle W. Gano, Ph.D. (President and Chief Executive Officer), Matt Abernethy (Chief Financial Officer), Andrew Ratz (Chief Technical Operations Officer)

Tech Stack

Databricks

Analytics

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Neurocrine Biosciences?

Neurocrine Biosciences uses the firstinitiallast format, so Jane Smith would be jsmith@neurocrine.com.

What approved medicines does Neurocrine Biosciences currently market?

Neurocrine Biosciences markets three approved medicines: INGREZZA (valbenazine) for tardive dyskinesia and Huntington's disease chorea, CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia, and VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome.

Who leads Neurocrine Biosciences as CEO in 2026?

Kyle W. Gano, Ph.D. serves as President and Chief Executive Officer of Neurocrine Biosciences. He was appointed to the role in October 2024 after previously serving as the company's Chief Business Development and Strategy Officer.

How far along is Neurocrine Biosciences' osavampator program for major depressive disorder?

Osavampator, a potential first-in-class investigational AMPA receptor modulator, is currently in a Phase 3 registrational program as an adjunctive therapy for adults with major depressive disorder. If you need to reach a specific Neurocrine Biosciences contact on the program, Clay can help identify and verify the right person.

How many employees does Neurocrine Biosciences have and where is it headquartered?

Neurocrine Biosciences employs approximately 2,332 people and is headquartered in San Diego, CA. The company focuses on neurology, psychiatry, and endocrinology, with its commercial, research, and development operations based there.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles